 |
Pharmasset Announces Intent to Amend QUANTUM Trial
Dec 16, 2011
|
10.1 KB |
|
| |
PRINCETON, N.J., Dec. 16, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the company will amend the design of the QUANTUM Phase 2b trial of the guanine nucleotide analog PSI-938 and discontinue all treatment arms with a regimen containing PSI-938. There are 235 individuals with hepatitis C virus (HCV) in the study who are...
|
|
Gilead Sciences to Acquire Pharmasset, Inc. for $11 Billion
Nov 21, 2011
|
19.8 KB |
|
| |
- Accelerates Development of All-Oral Regimen for the Treatment of
HCV -
- Leverages Gilead's Infrastructure and Expertise in Antiviral
Drug Development, Manufacturing and Commercialization -
FOSTER CITY, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--
Gi...
|
|
Pharmasset Reports Fiscal Year End 2011 Financial Results
Nov 14, 2011
|
22.9 KB |
|
| |
PRINCETON, N.J., Nov. 14, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the fiscal year ended September 30, 2011. At fiscal year end Pharmass...
|
|
Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
Nov 13, 2011
|
10.7 KB |
|
| |
PRINCETON, N.J., Nov. 13, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Lazard Capital Markets 8th Annual Healthcare Conference to be held November 15 to 16, 2011 at the Pierre Hotel, New York. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the com...
|
|
Pharmasset to Present at Credit Suisse First Boston Healthcare Conference
Nov 8, 2011
|
10.6 KB |
|
| |
PRINCETON, N.J., Nov. 8, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Credit Suisse First Boston Healthcare Conference to be held November 8 to 10, 2011 at the Biltmore Hotel, Phoenix, Arizona. Patrick Higgins, Pharmasset's Executive Vice President, will provide an overview of the company at the...
|
|
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Nov 4, 2011
|
12.2 KB |
|
| |
PRINCETON, N.J., Nov. 4, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Sunday, November 6, 2011 starting at 6:30pm PT. During this webcast, management will review Pharmasset's progress on the programs that are the s...
|
|
Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
Nov 1, 2011
|
13.9 KB |
|
| |
PRINCETON, N.J., Nov. 1, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced the initiation of a Phase 3 program with the hepatitis C virus (HCV) nucleotide analog, PSI-7977. This pivotal program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in patients with HCV, independent of viral genotype ...
|
|
Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C
Oct 10, 2011
|
13.3 KB |
|
| |
PRINCETON, N.J., Oct. 10, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the addition of two treatment arms to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The rapid and consistent antiviral effects and high barrier to resistance demonstrated with PSI...
|
|
Pharmasset to Present at Two Upcoming Conferences
Sep 16, 2011
|
10.8 KB |
|
| |
PRINCETON, N.J., Sept. 16, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the UBS Global Life Sciences Conference to be held September 19 to 21, 2011 at the Grand Hyatt Hotel, New York and the JMP Securities Healthcare Conference to be held September 27 to 28, 2011 at the St. Regis, New York. Schaefer...
|
|
Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
Sep 13, 2011
|
11.8 KB |
|
| |
PRINCETON, N.J., Sept. 13, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b, international study of PSI-7977 and PSI-938, two nucleotide analog polymerase inhibitors for the treatment of chronic hepatitis C (HCV). The QUANTUM trial will evaluate interferon-free regimens of PSI-7977 400mg QD...
|
|
Pharmasset to Present at Two Upcoming Conferences
Sep 6, 2011
|
10.8 KB |
|
| |
PRINCETON, N.J., Sept. 6, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Robert W. Baird 2011 Healthcare Conference to be held September 7 to 8, 2011 at the New York Palace Hotel, New York and the Morgan Stanley Global Healthcare Conference to be held September 13 to 14, 2011 at the Grand Hyatt, N...
|
|
Pharmasset Announces 91% SVR12 From the PROTON Trial in Subjects With Hepatitis C Genotype 1
Sep 6, 2011
|
11.9 KB |
|
| |
PRINCETON, N.J., Sept. 6, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been tr...
|
|
PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
Aug 24, 2011
|
10.8 KB |
|
| |
PRINCETON, N.J., Aug. 24, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) has received fast track designation from the U.S. Food and Drug Administration (FDA) for PSI-938 for the treatment of chronic hepatitis C virus (HCV) infection. PSI-938 is an oral guanosine nucleotide analog polymerase inhibitor of HCV.
In March 2011, Pharmasset pres...
|
|
Pharmasset Announces Two-for-One Forward Stock Split
Aug 9, 2011
|
10.1 KB |
|
| |
PRINCETON, N.J., Aug. 9, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that its Board of Directors declared a two-for-one split of Pharmasset's common stock, par value $0.001 per share, in the form of a 100% common stock dividend. Stockholders of record as of the close of business on August 22, 2011 will receive one additional sha...
|
|
Pharmasset to Present at Canaccord Genuity Growth Conference
Aug 7, 2011
|
10.7 KB |
|
| |
PRINCETON, N.J., Aug. 7, 2011 /PRNewswire/ --- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the Canaccord Genuity Growth Conference to be held August 10 to 11, 2011 at the Intercontinental Hotel, Boston, Massachusetts. Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the co...
|
|
Pharmasset Reports Fiscal Third Quarter 2011 Financial Results
Jul 25, 2011
|
18.3 KB |
|
| |
PRINCETON, N.J. , July 25, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended June 30, 2011.
Financial Results
Revenues w...
|
|
Pharmasset Announces Final SVR Data from PROTON trial with PSI-7977 in Subjects Infected with Hepatitis C Infection Genotype 2 or 3
Jul 20, 2011
|
12.0 KB |
|
| |
PRINCETON, N.J., July 20, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the final sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 2 or 3 who have not ...
|
|
Pharmasset Enters into a Clinical Collaboration Agreement with Tibotec Pharmaceuticals for a Combination Study in Patients Chronically Infected with Hepatitis C
Jul 6, 2011
|
11.8 KB |
|
| |
PRINCETON, N.J., July 6, 2011 /PRNewswire/ -- Pharmasset, Inc. (NASDAQ: VRUS), announced today that it has entered into a clinical collaboration agreement with Tibotec Pharmaceuticals to evaluate in a Phase 2 study the safety and efficacy of PSI-7977, Pharmasset's investigational nucleotide polymerase inhibitor, in combination with TMC435, Tibotec ...
|
|
Pharmasset Announces Issuance of U.S. Patent for PSI-7977
Jun 22, 2011
|
11.5 KB |
|
| |
PRINCETON, N.J., June 22, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that the United States Patent and Trademark Office has issued U.S. patent 7,964,580 ("the '580 patent") titled "Nucleoside Phosphoramidate Prodrugs". This patent generally relates to the composition of matter of PSI-7977 and its diastereomeric mixture for the t...
|
|
Pharmasset Announces the Expansion of the ELECTRON Trial in Chronic Hepatitis C
Jun 8, 2011
|
12.5 KB |
|
| |
PRINCETON, N.J., June 8, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV). The rapid and consistent antiviral effects and high barrier to resistance demonstrated with...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz
